When was BioSymetrics founded?

BioSymetrics was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is BioSymetrics located?

BioSymetrics is headquartered in New York City, United States.

Who is the current CEO of BioSymetrics?

Anthony Iacovone of BioSymetrics. They have also founded 2 companies.

How many employees does BioSymetrics have?

As of Jul 01, 2024, the latest employee count at BioSymetrics is 25.

Is BioSymetrics a funded company?

BioSymetrics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Aug 04, 2021.

When was the latest funding round of BioSymetrics?

BioSymetrics' latest funding was a $***** Series A round on Aug 04, 2021, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $1B in funding in 2026 to date.

Where does BioSymetrics rank among its competitors?

BioSymetrics ranks 28th amongst 166 active competitors, of which 68 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Antiverse, which secured $9.3M in Mar, 2026.

Who are the top competitors of BioSymetrics?

BioSymetrics' top competitors include Evotec, DNAnexus and Insitro. Among them, Antiverse secured the most recent funding round in March, 2026.

BioSymetrics - 2026 Company Profile, Team, Funding & Competitors

BioSymetrics is a series A company based in New York City (United States), founded in 2015 by Anthony Iacovone. It operates as a Provider of a cognitive computing-based biomedical intelligence platform. BioSymetrics has raised $4.87M in funding. The company has 166 active competitors, including 68 funded and 10 that have exited. Its top competitors include companies like Evotec, DNAnexus and Insitro.

Company Details

Provider of a cognitive computing-based biomedical intelligence platform. It provides pre-processing, analytics and zero-latency machine learning for cases in bioinformatics, R&D clinical informatics, target discovery, and computational biology. It also provides predictive analytics on many kinds of R&D and healthcare data.

Website: www.biosymetrics.com
Social
Email ID: *****@BioSymetrics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

New York City, United States

Stage

Series A

Total Funding

$4.87M in 1 round

Latest Funding Round

Series A, Aug 04, 2021, $*****

Investors

AJI Capital & 2 more

Ranked

28^th among 166 active competitors

Employee Count

25 as on Jul 01, 2024

Similar Companies

Evotec & 217 more

View BioSymetrics' full profile

BioSymetrics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LUNFARDA LLC CIN: 6223993 , United States, Active	Jul 20, 2021	-	-	-

BioSymetrics has raised a total funding of $4.87M over 1 round. BioSymetrics has 3 institutional investors.

Here is the list of recent funding rounds of BioSymetrics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 04, 2021	3115624	Series A	3325649	4694684	3125264	4729888

Access funding benchmarks and valuations. Sign up today!

View details of BioSymetrics's funding rounds and investors

The founders of BioSymetrics is Anthony Iacovone.

Here are the details of BioSymetrics' key team members:

Anthony Iacovone: Co-Founder & CEO of BioSymetrics and founder of 2 other companies, SnapStudy.ai and AdTheorent. They serve on the board of 1 company.
Contact Info: 2 email addresses

View details of BioSymetrics's Founder profiles and Board Members

BioSymetrics' employee count trend

BioSymetrics has 25 employees as of Jul 24. Here is BioSymetrics's employee count trend over the years:

Uncover BioSymetrics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioSymetrics include Evotec, DNAnexus and Insitro. Here is the list of Top 10 competitors of BioSymetrics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	Provider of drug discovery alliance and development services for biopharma sector	$25M	TVM Capital Life Science, Mubadala & 20 others	76/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
3rd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
4th	Atomwise 2012, San Francisco (United States), Series B	Developer of artificial intelligence platform for small molecule drug discovery	$219M	DCVC, B Capital & 27 others	68/100
5th	Antiverse 2017, Cardiff (United Kingdom), Series A	Developer of computational platform for de novo design of antibody therapeutics	$20M	Kadmos Capital, ACF Investors & 34 others	68/100
6th	Cytel 1987, Cambridge (United States), Acquired	Provider of data analysis and statistical solutions for the life sciences industry	$2M	New Mountain Capital, Autonomy Ventures & 3 others	67/100
7th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Viola Group, TLV Partners & 14 others	66/100
8th	Engine Biosciences 2014, Singapore (Singapore), Series A	Developer of platform technology for combinatorial genetics discovery	$86M	Polaris Partners, DHVC & 18 others	66/100
9th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
10th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$237M	Andreessen Horowitz, CPP Investments & 11 others	65/100
28th	BioSymetrics 2015, New York City (United States), Series A	Provider of a cognitive computing-based biomedical intelligence platform	$4.87M	AJI Capital, Mogility Capital & 1 others	51/100